ISRCTN75147488已完成不适用
A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancer
Medical Research Council (MRC) (UK)0 个研究点目标入组 700 人开始时间: 2001年2月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Metastatic breast cancer previously untreated except in adjuvant setting
- •2. Exposure to anthracyclines limited
- •3. Treatment free interval more than 6 months
- •4. Normal ejection fraction
排除标准
- •History of cardiac disease
研究者
相似试验
已完成
3 期
IBCSG 15-95 - Randomised trial of high-dose epirubicin and cyclophosphamide x 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide x 4 followed by cyclophosphamide, methotrexate, and 5-fluoruracil x 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (<=65 yrs) patientsCancer - BreastBreast CancerACTRN12607000025437International Breast Cancer Study Group300
已完成
2 期
Phase II trial of Epirubicin / Cyclophosphamide (EC) followed by Nab-paclitaxel as neoadjuvant chemotherapy for node positive breast cancerBreast CancerJPRN-UMIN000009853Dokkyo Medical University23
已完成
不适用
A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancerBiliary TractBiliaryCancerISRCTN73941125The Royal Marsden NHS Foundation Trust (UK)
进行中（未招募）
1 期
Randomized trial of sequential epirubicin and docetaxel against docetaxel in patients with early operable breast cancer. - READ TOP2AWomen with operable breast cancer and increased risk of recurrenceEUCTR2007-003126-15-DKDBCG1,932
进行中（未招募）
1 期
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine and Herceptin in Early Breast Cancerearly HER-2 breast cancerEUCTR2004-002030-19-ATAUSTRIAN BREAST CANCER STUDY GROUP536